RSP Systems A/S, an Odense, Denmark-based non-invasive diagnostics company, held a €3.85m second closing of its Series B funding.
Backers included Trumpf Venture, among other new and existing investors. This brought the round to €10.35m.
The company intends to use the capital to fund clinical trials and to prepare for regulatory approval and market launch in Europe.
Led by CEO Andreas Jenne, RSP System is a medtech company founded in 2006 as a spinout from the University of Southern Denmark, applying Raman spectroscopy for human diagnostics.
Over the past 6 years, the company has aimed for glucose monitoring and has now developed a prototype which shows target performance in clinical studies on diabetic patients at Odense University Hospital. RSP System uses this platform for its first non-invasive glucose monitor for diabetic patients.